Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asparaginase Wolinella succinogenes-derived - Rare Disease Therapeutics

Drug Profile

Asparaginase Wolinella succinogenes-derived - Rare Disease Therapeutics

Alternative Names: Wolinella succinogenes-derived asparaginase; rWS

Latest Information Update: 01 Jun 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Childrens Hospital Los Angeles
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Sep 2015 Biomarkers information updated
  • 29 Aug 2005 correspondence from RDT 26 Aug 2005. Rewrote intro slightly
  • 21 Jun 2004 Phase-I/II clinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top